Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio
Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.
You may also be interested in...
Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.